Remimazolam in the Extraction of Impacted Wisdom Teeth (NCT05350085) | Clinical Trial Compass
UnknownNot Applicable
Remimazolam in the Extraction of Impacted Wisdom Teeth
China150 participantsStarted 2022-04-18
Plain-language summary
Benzodiazepines, represented by midazolam, are often used for sedation in outpatient surgery in dentistry. However, midazolam has the problems of slow consciousness recovery and long recovery time, which brings trouble to the patients. Remimazolam is a new type of ultra short acting sedative anesthetic. Compared with other similar products, remimazolam has faster effect, rapid metabolism and has no accumulation, which may mean that compared with midazolam, remimazolam has a better clinical application prospect in dental outpatient surgery.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Have mandibular impacted wisdom teeth that need to be extracted;
✓. Have a body mass index (BMI) between 18.5 and 30 kg/m2;
✓. Are aged between 18 and 60 years;
✓. Have American Society of Anesthesiology (ASA) classification grade of I-II;
✓. Have Modified Dental Anxiety Scale (MDAS) score \> 15; and
✓. Volunteered to accept intravenous sedation.
Exclusion criteria
✕. Are pregnant;
✕. Experience respiratory infections, asthma attack or persistent state;
✕. Have contraindications to anaesthesia or a previous abnormal surgical anaesthesia recovery history;
✕. Have severe cardiopulmonary insufficiency;
✕
What they're measuring
1
Recovery time of complete alertness
Timeframe: During treatment in hospital, an expected average of 2 hours